Appraisal in progress
Indication |
|
| Status: In progress | |
With prednisolone for the treatment of newly-diagnosed high-risk, metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT). |
|
Medicine details |
|
| Medicine name | abiraterone (generic) |
| Formulation | 250 mg and 500 mg tablet |
| Reference number | 6441 |
| Indication | As above |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | Limited |
| Status | In progress |
| Scrutiny Panel meeting date | 09/01/2025 |
| LOWMAG meeting date | TBC |
| AWMSG meeting date | TBC |
| Date of issue | TBC |
| Further information Abiraterone (generic) is considered suitable for a limited reassessment by the AWMSG Scrutiny Panel at their meeting on 09/01/2025. |
|